Stockscreener 앱 받기
4.02%
시간 외 거래:
Altimmune Inc 주식(ALT)의 최신 뉴스
Trading (ALT) With Integrated Risk Controls - news.stocktradersdaily.com
Nasal Vaccines Market Top Companies StudyVaxart, Inc, FluGen Inc, Altimmune, Inc, Sinovac Biotech Ltd. - openPR.com
Altimmune's US$42m Market Cap Fall Books Insider Losses - Yahoo
Coulter Partners places seasoned biopharmaceutical industry executives to Altimmune Board of Directors - Hunt Scanlon Media
Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com Canada
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
H.C. Wainwright maintains Buy rating on Altimmune stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on Altimmune stock - Investing.com India
8 Analysts Assess Altimmune: What You Need To Know - Benzinga
Altimmune’s Pemvidutide: A Promising Catalyst with Blockbuster Potential and Strong Financial Backing - TipRanks
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon - MSN
JMP maintains Altimmune stock target at $25 on Phase 2b optimism - Investing.com
PharmAthene stock hits 52-week low at $5.1 amid challenges By Investing.com - Investing.com South Africa
PharmAthene stock hits 52-week low at $5.1 amid challenges - Investing.com
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Class Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move - Yahoo
Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts - MSN
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine (ALT) - Seeking Alpha
Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook - Investing.com Canada
Altimmune’s SWOT analysis: pemvidutide’s potential reshapes obesity and MASH stock outlook By Investing.com - Investing.com South Africa
Altimmune rises as buyout rumors follow R&D updates - MSN
Altimmune CFO Gregory Weaver purchases $51,996 in stock By Investing.com - Investing.com Australia
Altimmune Outlines Pemvidutide Plans In MASH And Beyond - insights.citeline.com
Altimmune soars amid takeover speculation - MSN
Altimmune stock rises amid buyout and R&D news(ALT:NASDAQ) - Seeking Alpha
(ALT) Trading Advice - Stock Traders Daily
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders - Benzinga
Stifel maintains Buy on Altimmune stock, $18 price target - Investing.com India
Stifel maintains Buy on Altimmune stock, $18 price target By Investing.com - Investing.com UK
Altimmune rises on plans to test obesity drug for alcohol use disorder, other conditions - TradingView
Altimmune CFO Gregory Weaver purchases $51,996 in stock - Investing.com India
Citizens JMP reiterates Altimmune stock with $25 target By Investing.com - Investing.com South Africa
Citizens JMP reiterates Altimmune stock with $25 target - Investing.com
2.04%
2.60%
자본화:
|
볼륨(24시간):